FDA Warns Hims & Hers Compounder Over Safety Violations

Got story updates? Submit your updates here. ›

The FDA has issued a warning to MedisourceRx, a compounding pharmacy owned by Hims & Hers, over a series of concerning incidents uncovered during an inspection last year. The violations include a failure to promptly report a patient's severe adverse reaction to a compounded medication, as well as issues with bugs and other problems at the Los Alamitos, California facility.

Why it matters

This case highlights the delicate balance between pharmaceutical innovation and regulatory oversight when it comes to compounding pharmacies, which offer customized medications. The incident raises questions about how to ensure these pharmacies maintain the highest safety standards and the role the FDA should play in monitoring and enforcing those standards.

The details

During the FDA inspection in May and June 2025, inspectors discovered that a patient had experienced a severe stomach reaction after taking a compounded version of the weight loss medication semaglutide, leading to a three-night hospital stay. However, the pharmacy failed to report this adverse event to the FDA within the required 15-day period. The inspection also uncovered other issues at the facility, including the presence of bugs, which were cited as violations.

• The adverse event occurred in January 2025, just four months after Hims & Hers acquired MedisourceRx.
• The FDA inspection took place in May and June 2025.
• The FDA warning letter was issued in late 2025, six months after the inspection.

What’s next

The FDA's warning letter has sparked debate about the timeliness of the agency's actions and whether more could have been done to prevent potential harm to patients. The case also invites discussion on the challenges of regulating the evolving compounding pharmacy industry to ensure the highest safety standards.